Lisata Therapeutics (NASDAQ:LSTA) Shares Up 0.9% – Still a Buy?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares rose 0.9% during mid-day trading on Monday . The stock traded as high as $2.33 and last traded at $2.28. Approximately 26,865 shares changed hands during trading, an increase of 27% from the average daily volume of 21,225 shares. The stock had previously closed at $2.26.

Lisata Therapeutics Price Performance

The firm’s 50-day moving average price is $2.27 and its 200-day moving average price is $2.71. The company has a market cap of $19.65 million, a price-to-earnings ratio of -0.91 and a beta of 1.00.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.21. The company had revenue of $1.00 million during the quarter. On average, sell-side analysts anticipate that Lisata Therapeutics, Inc. will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 45.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,226 shares of the company’s stock after purchasing an additional 7,886 shares during the period. Dimensional Fund Advisors LP owned approximately 0.30% of Lisata Therapeutics worth $75,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.